-
Product Insights
V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation – Drugs In Development, 2023
Global Markets Direct’s V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation provides in depth analysis on V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGS-v PLUS in Zika Virus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGS-v PLUS in Zika Virus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGS-v PLUS in Zika Virus Infections Drug Details: AGS-v PLUS...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGS-v PLUS in West Nile Encephalitis (West Nile Fever)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGS-v PLUS in West Nile Encephalitis (West Nile Fever) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGS-v PLUS in West Nile Encephalitis (West...
-
Sector Analysis
NewNetherlands Cards and Payments – Opportunities and Risks to 2028
Netherlands Cards and Payments Market Report Overview The annual value of card transactions in the Netherlands cards and payments market was $205.1 billion in 2023. The Dutch cards and payments market will grow at a CAGR of more than 6% during 2024-2028. Dutch banks are progressively switching from Maestro and V PAY to Mastercard- and Visa-branded debit cards. Since July 2023, Mastercard and Visa have no longer issued Maestro and V PAY cards. Netherlands Card Transactions Outlook, 2024-2028 ($ Billion)...
-
Thematic Analysis
NewPackaging M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Packaging Sector
-
Thematic Analysis
NewBanking and Payments M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Banking & Payments Sector
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-5475
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-5475 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Catequentinib Hydrochloride in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Catequentinib Hydrochloride in Metastatic Ovarian Cancer Drug Details: Catequentinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Catequentinib Hydrochloride in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Catequentinib Hydrochloride in Metastatic Pancreatic Cancer Drug Details: Catequentinib...
-
New
Likelihood of Approval and Phase Transition Success Rate Model – Catequentinib Hydrochloride in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Catequentinib Hydrochloride in Cervical Cancer Drug Details: Catequentinib hydrochloride (AL-3818)...